Comparison of in vitro antifungal activities of free and liposome- encapsulated nystatin with those of four amphotericin B formulations

Antimicrobial Agents and Chemotherapy

Volumn 42, Issue 6, 1998, Pages 1412-1416

  Johnson, Elizabeth M ^a   Ojwang, Joshua O ^b   Szekely, Adrien ^a   Wallace, Thomas L ^b   Warnock, David W ^a,c  

^a PUBLIC HEALTH ENGLAND   (United Kingdom)

^b Antigenics Inc   (United States)

^c NHS BLOOD AND TRANSPLANT   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B CHOLESTEROL SULFATE; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; LIPOSOME; NYSTATIN;

ANTIBIOTIC SENSITIVITY; ANTIFUNGAL ACTIVITY; ARTICLE; ASPERGILLUS; CANDIDA; CRYPTOCOCCUS NEOFORMANS; DRUG FORMULATION; MICROENCAPSULATION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL;

EID: 0031805398     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.42.6.1412     Document Type: Article

References (30)

1. Anaissie, E., V. Paetznick, R. Proffitt, J. Adler-Moore, and G. P. Bodey. 1991. Comparison of the in vitro antifungal activity of free and liposome-encapsulated amphotericin B. Eur. J. Clin. Microbiol. Infect. Dis. 10:665-668.
2. Boutati, E. I., H. C. Maltezou, G. Lopez-Berestein, S. E. Vartivarian, and E. J. Anaissie. 1995. Phase I study of maximum tolerated dose of intravenous liposomal nystatin (L-NYST) for the treatment of refractory febrile neutropenia (RFN) in patients with hematological malignancies, abstr. LM22, p. 330. In Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
3. Broughton, M. C., M. Bard, and N. D. Lees. 1991. Polyene resistance in ergosterol producing strains of Candida albicans. Mycoses 34:75-83.
4. Brown, R., E. L. Hazen, and A. Mason. 1953. Effect of fungicidin (nystatin) in mice injected with lethal mixtures of aureomycin and Candida albicans. Science 117:609-610.
5. Campbell, C. C., E. T. O'Dell, and G. B. Hill. 1955. Therapeutic activity of nystatin in experimental systemic mycotic infections. Antibiot. Annu. 1955: 858-862.
6. Cossum, P. A., J. Wyse, V. Simmons, T. L. Wallace, and A. Rios. 1996. Pharmacokinetics of Nyotran (liposomal nystatin) in human patients, abstr. A88, p. 17. In Abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
7. Drouchet, E., J. Schwarz, and E. Bingham. 1956. Evaluation of the action of nystatin on Histoplasma capsulatum in vitro and in hamsters and mice. Antibiot. Chemother. (Washington, D.C.) 6:23-35.
8. Gallis, H. A., R. H. Drew, and W. W. Pickard. 1990. Amphotericin B: 30 years of clinical experience. Rev. Infect. Dis. 12:308-329.
9. Gonzalez, C. E., N. Giri, D. Shetty, K. Kligys, W. Love, T. Sein, R. Schaufele, C. Lyman, J. Bacher, and T. J. Walsh. 1996. Efficacy of a lipid formulation of nystatin against invasive pulmonary aspergillosis, abstr. B54, p. 31. In Abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
10. Gordon, L. E., C. E. Smith, and D. S. Wedin. 1955. Nystatin (Mycostatin) therapy in experimental coccidioidomycosis. Am. Rev. Tuberc. Pulm. Dis. 72:64-70.
11. Hanson, L. H., and D. A. Stevens. 1992. Comparison of antifungal activity of amphotericin B deoxycholate suspension with that of amphotericin B cholesteryl sulfate colloidal dispersion. Antimicrob. Agents Chemother. 36:486-488.
12. Hazen, E. L., and R. Brown. 1951. Fungicidin, an antibiotic produced by a soil actinomycete. Proc. Soc. Exp. Biol. Med. 76:93-97.
13. Hiemenz, J. W., and T. J. Walsh. 1996. Lipid formulations of amphotericin B: recent progress and future directions. Clin. Infect. Dis. 22(Suppl. 2): S133-S144.
14. Hopfer, R. L., K. Mills, R. Mehta, G. Lopez-Berestein, V. Fainstein, and G. P. Bodey. 1984. In vitro antifungal activities of amphotericin B and liposome-encapsulated amphotericin B. Antimicrob. Agents Chemother. 25: 387-389.
15. Janoff, A. S., W. R. Perkins, S. L. Saletan, and C. E. Swenson. 1993. Amphotericin B lipid complex (ABLC): a molecular rationale for the attenuation of amphotericin B related toxicities. J. Liposome Res. 3:451-471.
16. Legrand, P., M. Cheron, L. Leroy, and J. Bolard. 1997. Release of amphotericin B from delivery systems and its action against fungal and mammalian cells. J. Drug Targeting 4:311-319.
17. Lopez-Berestein, G., R. Mehta, R. L. Hopfer, K. Mills, L. Kasi, K. Mehta, V. Fainstein, M. Luna, E. M. Hersh, and R. Juliano. 1983. Treatment and prophylaxis of disseminated Candida albicans infection in mice with liposomal encapsulated amphotericin B. J. Infect. Dis. 147:939-945.
18. Mehta, R. T., R. L. Hopfer, L. A. Gunner, R. L. Juliano, and G. Lopez-Berestein. 1987. Formulation, toxicity, and antifungal activity in vitro of liposome-encapsulated nystatin as therapeutic agent for systemic candidiasis. Antimicrob. Agents Chemother. 31:1897-1900.
19. Mehta, R. T., R. L. Hopfer, T. McQueen, R. L. Juliano, and G. Lopez-Berestein. 1987. Toxicity and therapeutic effects in mice of liposome-encapsulated nystatin for systemic fungal infections. Antimicrob. Agents Chemother. 31:1901-1903.
20. National Committee for Clinical Laboratory Standards. 1997. Reference method for broth dilution antifungal susceptibility testing of yeasts. Approved standard. Document M27-A. National Committee for Clinical Laboratory Standards, Wayne, Pa.
21. Newcomer, V. D., E. T. Wright, T. H. Sternberg, J. H. Graham, R. H. Wier, and R. O. Egeberg. 1955. Evaluation of nystatin in the treatment of coccidioidomycosis in man, p. 260-267. In T. H. Sternberg and V. D. Newcomer (ed.), Therapy of fungus diseases. Little, Brown and Co., Boston, Mass.
22. Pahls, S., and A. Schaffner. 1994. Comparison of the activity of free and liposomal amphotericin B in vitro and in a model of systemic and localized murine candidiasis. J. Infect. Dis. 169:1057-1061.
23. Procknow, J. J., and C. G. Loosli. 1958. Treatment of deep mycoses. Arch. Intern. Med. 101:765-802.
24. Ralph, E. D., A. M. Khazindar, K. R. Barber, and C. W. M. Grant. 1991. Comparative in vitro effects of liposomal amphotericin B, amphotericin B deoxycholate, and free amphotericin B against fungal strains determined by using MIC and minimum lethal concentration susceptibility studies and time-kill curves. Antimicrob. Agents Chemother. 35:188-191.
25. Richardson, M. D., and D. W. Warnock. 1997. Fungal infection: diagnosis and management, 2nd ed. Blackwell Scientific Publications, Oxford, United Kingdom.
26. Solotorovsky, M., G. Quabeck, and S. Winsten. 1958. Antifungal activity of candidin, nystatin, euclin, and stilbamidine against experimental infections in the mouse. Antibiot. Chemother. (Washington, D.C.) 8:364-371.
27. Stanley, V. C., and M. P. English. 1965. Some effects of nystatin on the growth of four Aspergillus species. J. Gen. Microbiol. 40:107-118.
28. van Etten, E. W. M., M. T. Ten Kate, L. E. T. Stearne, and I. A. J. M. Bakker-Woudenberg. 1995. Amphotericin B liposomes with prolonged circulation in blood: in vitro antifungal activity, toxicity, and efficacy in systemic candidiasis in leukopenic mice. Antimicrob. Agents Chemother. 39:1954-1958.
29. Wallace, T. L., V. Paetznick, P. A. Cossum, G. Lopez-Berestein, J. H. Rex, and E. Anaissie. 1997. Activity of liposomal nystatin against disseminated Aspergillus fumigatus infection in neutropenic mice. Antimicrob. Agents Chemother. 41:2238-2243.
30. Woods, R. A., M. Bard, I. E. Jackson, and D. J. Drutz. 1974. Resistance to polyene antibiotics and correlated sterol changes in two isolates of Candida tropicalis from a patient with amphotericin B-resistant funguria. J. Infect. Dis. 129:53-58.